Skip to main content
Sign In

Schlaepfer Research Lab

Genitourinary Cancer


Dr. Schlaepfer’s long term goal is to use her molecular and lipid metabolism training and apply it to investigate how prostate cancer cells use lipids for growth and survival. Her current project focuses on the role of the CPT1A enzyme in prostate cancer growth. CPT1A functions as a gatekeeper, mediating the entry of lipid into the mitochondria for oxidation and growth. Dr. Schlaepfer is using clinically safe drugs from the cardiovascular/obesity field to target lipid oxidation and elucidate metabolic weaknesses that can be exploited in the clinic for more effective imaging and therapeutic combinations.


PhD, University of Colorado Boulder

Isabel Schlaepfer was born in Madrid, Spain and attended the Universidad Complutense and the Universidad de Navarra in Pamplona, where she graduated with a degree in Biochemistry. She joined the University of Colorado AMC in 1992 in the Division of Endocrinology, Metabolism and Diabetes, where she worked as a PRA for over a decade on lipid metabolism and genetics. She obtained her PhD from the Department of Integrative Physiology in 2008 plus a certificate in Behavioral Genetics from IBG in Boulder. In 2012 she joined the Department of Pharmacology in Denver as a Research Instructor. Dr. Schlaepfer is currently an Assistant Professor of Medicine in the Division of Medical Oncology at the CU Anschutz medical campus.


  • K01CA168934 - Targeting Lipid Oxidation for Prostate Cancer Imaging and Therapy Pilot Project Award - Enhancement of FDG-PET with metabolic inhibitors Pilot Project Junior Faculty Award - Pilot study to enhance 18F-FDG-PET imaging of human prostate cancer with ranolazine
  • American Cancer Society RSG; CPT1A-mediated fat oxidation as a therapeutic target in prostate cancer.